Skip to main content
Top
Published in: BMC Cancer 1/2014

Open Access 01-12-2014 | Research article

Outcome after intensity modulated radiotherapy for anaplastic thyroid carcinoma

Authors: Xiayun He, Duanshu Li, Chaosu Hu, Zhuoying Wang, Hongmei Ying, Yi Wu

Published in: BMC Cancer | Issue 1/2014

Login to get access

Abstract

Background

Anaplastic thyroid carcinoma (ATC) is a malignancy with one of the highest fatality rates. We reviewed our recent clinical experience with intensity modulated radiotherapy (IMRT) combined with surgery and chemotherapy for the management of ATC.

Methods

13 patients with ATC who were treated by IMRT in our institution between October 2008 and February 2011, have been analyzed. The target volume for IMRT was planned to include Gross tumor volume (GTV): primary tumor plus any N + disease (66 Gy/33 F/6.6 W), with elective irradiation of thyroid bed, bilateral level II through VI and mediastinal lymph nodes to the level of the carina (54-60 Gy). Seven patients received surgical intervention and eleven patients had chemotherapy.

Results

The median radiotherapy dose to GTV was 60 Gy/30 fractions/6 weeks. The median survival time of the 13 patients was 9 months. The direct causes of death were distant metastases (75%) and progression of the locoregional disease (25%). Ten patients were spared dyspnea and tracheostomy because their primary neck lesion did not progress.

Conclusion

The results showed that IMRT combined by surgery and chemotherapy for ATC might be beneficial to improve locoregional control. Further new therapies are needed to control metastases.
Literature
1.
go back to reference Baroli A, Pedrazzini L, Lomuscio G, Marzoli L: Anaplastic thyroid carcinoma. Practical aspects of multimodal therapy and data emerging from a 40-year experience at a single Italian institution. Minerva Endocrinol. 2010, 35: 9-16.PubMed Baroli A, Pedrazzini L, Lomuscio G, Marzoli L: Anaplastic thyroid carcinoma. Practical aspects of multimodal therapy and data emerging from a 40-year experience at a single Italian institution. Minerva Endocrinol. 2010, 35: 9-16.PubMed
2.
go back to reference Roche B, Larroumets G, Dejax C, Kwiatkowsi F, Desbiez F, Thieblot P, Tauveron I: Epidemiology, clinical presentation, treatment and prognosis of a regional series of 26 anaplastic thyroid carcinomas (ATC): comparison with the literature. Ann Endocrinol(Paris). 2010, 71: 38-45. 10.1016/j.ando.2009.10.013.CrossRef Roche B, Larroumets G, Dejax C, Kwiatkowsi F, Desbiez F, Thieblot P, Tauveron I: Epidemiology, clinical presentation, treatment and prognosis of a regional series of 26 anaplastic thyroid carcinomas (ATC): comparison with the literature. Ann Endocrinol(Paris). 2010, 71: 38-45. 10.1016/j.ando.2009.10.013.CrossRef
3.
go back to reference Chen J, Tward JD, Shrieve DC, Hitchcock YJ: Surgery and radiotherapy improves survival in patients with anaplastic thyroid carcinoma: analysis of the surveillance, epidemiology, and end results 1983-2002. Am J Clin Oncol. 2008, 31: 460-464. 10.1097/COC.0b013e31816a61f3.CrossRefPubMed Chen J, Tward JD, Shrieve DC, Hitchcock YJ: Surgery and radiotherapy improves survival in patients with anaplastic thyroid carcinoma: analysis of the surveillance, epidemiology, and end results 1983-2002. Am J Clin Oncol. 2008, 31: 460-464. 10.1097/COC.0b013e31816a61f3.CrossRefPubMed
4.
go back to reference Ito K, Hanamura T, Murayama K, Okada T, Watanabe T, Harada M, Ito T, Koyama H, Kanai T, Maeno K, Mochizuki Y, Amano J: Multimodality therapeutic outcomes in anaplastic thyroid carcinoma: improved survival in subgroups of patients with localized primary tumors. Head Neck. 2012, 34: 230-237. 10.1002/hed.21721.CrossRefPubMed Ito K, Hanamura T, Murayama K, Okada T, Watanabe T, Harada M, Ito T, Koyama H, Kanai T, Maeno K, Mochizuki Y, Amano J: Multimodality therapeutic outcomes in anaplastic thyroid carcinoma: improved survival in subgroups of patients with localized primary tumors. Head Neck. 2012, 34: 230-237. 10.1002/hed.21721.CrossRefPubMed
5.
go back to reference Tashima L, Mitzner R, Durvesh S, Goldenberg D: Dyspnea as a prognostic factor in anaplastic thyroid carcinoma. Eur Arch Otorhinolaryngol. 2012, 269: 1251-1255. 10.1007/s00405-011-1762-0.CrossRefPubMed Tashima L, Mitzner R, Durvesh S, Goldenberg D: Dyspnea as a prognostic factor in anaplastic thyroid carcinoma. Eur Arch Otorhinolaryngol. 2012, 269: 1251-1255. 10.1007/s00405-011-1762-0.CrossRefPubMed
7.
go back to reference Burnison CM: Lim S: Multimodal approach to anaplastic thyroid cancer. Oncology (Williston Park). 2012, 26: 378-384. Burnison CM: Lim S: Multimodal approach to anaplastic thyroid cancer. Oncology (Williston Park). 2012, 26: 378-384.
8.
go back to reference Lim SM, Shin SJ, Chung WY, Park CS, Nam KH, Kang SW, Keum KC, Kim JH, Cho JY, Hong YK, Cho BC: Treatment outcome of patients with anaplastic thyroid cancer: a single center experience. Yonsei Med J. 2012, 53: 352-357. 10.3349/ymj.2012.53.2.352.CrossRefPubMedPubMedCentral Lim SM, Shin SJ, Chung WY, Park CS, Nam KH, Kang SW, Keum KC, Kim JH, Cho JY, Hong YK, Cho BC: Treatment outcome of patients with anaplastic thyroid cancer: a single center experience. Yonsei Med J. 2012, 53: 352-357. 10.3349/ymj.2012.53.2.352.CrossRefPubMedPubMedCentral
9.
go back to reference Wein RO, Weber RS: Anaplastic thyroid carcinoma: palliation or treatment?. Curr Opin Otolaryngol Head Neck Surg. 2011, 19: 113-118. 10.1097/MOO.0b013e328343af3d.CrossRefPubMed Wein RO, Weber RS: Anaplastic thyroid carcinoma: palliation or treatment?. Curr Opin Otolaryngol Head Neck Surg. 2011, 19: 113-118. 10.1097/MOO.0b013e328343af3d.CrossRefPubMed
10.
go back to reference Akaishi J, Sugino K, Kitagawa W, Nagahama M, Kameyama K, Shimizu K, Ito K, Ito K: Prognostic factors and treatment outcomes of 100 cases of anaplastic thyroid carcinoma. Thyroid. 2011, 21: 1183-1189. 10.1089/thy.2010.0332.CrossRefPubMed Akaishi J, Sugino K, Kitagawa W, Nagahama M, Kameyama K, Shimizu K, Ito K, Ito K: Prognostic factors and treatment outcomes of 100 cases of anaplastic thyroid carcinoma. Thyroid. 2011, 21: 1183-1189. 10.1089/thy.2010.0332.CrossRefPubMed
11.
go back to reference Derbel O, Limem S, Ségura-Ferlay C, Lifante JC, Carrie C, Peix JL, Borson-Chazot F, Bournaud C, Droz JP, de la Fouchardière C: Results of combined treatment of anaplastic thyroid carcinoma (ATC). BMC Cancer. 2011, 11: 469-10.1186/1471-2407-11-469.CrossRefPubMedPubMedCentral Derbel O, Limem S, Ségura-Ferlay C, Lifante JC, Carrie C, Peix JL, Borson-Chazot F, Bournaud C, Droz JP, de la Fouchardière C: Results of combined treatment of anaplastic thyroid carcinoma (ATC). BMC Cancer. 2011, 11: 469-10.1186/1471-2407-11-469.CrossRefPubMedPubMedCentral
12.
go back to reference Swaak-Kragten AT, de Wilt JH: Schmitz Pl: Bontenbal M, Levendag PC. Multimodality treatment for anaplastic thyroid carcinoma treatment outcome in 75 patients. Radiother Oncol. 2009, 92: 100-104. 10.1016/j.radonc.2009.02.016.CrossRefPubMed Swaak-Kragten AT, de Wilt JH: Schmitz Pl: Bontenbal M, Levendag PC. Multimodality treatment for anaplastic thyroid carcinoma treatment outcome in 75 patients. Radiother Oncol. 2009, 92: 100-104. 10.1016/j.radonc.2009.02.016.CrossRefPubMed
13.
go back to reference Goutsouliak V, Hay JH: Anaplastic thyroid cancer in British Columbia 1985-1999: a population-based study. Clin Oncol (R Coll Radiol). 2005, 17: 75-78. 10.1016/j.clon.2004.07.013.CrossRef Goutsouliak V, Hay JH: Anaplastic thyroid cancer in British Columbia 1985-1999: a population-based study. Clin Oncol (R Coll Radiol). 2005, 17: 75-78. 10.1016/j.clon.2004.07.013.CrossRef
14.
go back to reference Foote RL, Molina JR, Kasperbauer JL, Lloyd RV, McIver B, Morris JC, Grant CS, Thompson GB, Richards ML, Hay ID, Smallridge RC, Bible KC: Enhanced survival in locoregionally confined anaplastic thyroid carcinoma: a single-institution experience using aggressive multimodal therapy. Thyroid. 2011, 21: 25-30. 10.1089/thy.2010.0220.CrossRefPubMed Foote RL, Molina JR, Kasperbauer JL, Lloyd RV, McIver B, Morris JC, Grant CS, Thompson GB, Richards ML, Hay ID, Smallridge RC, Bible KC: Enhanced survival in locoregionally confined anaplastic thyroid carcinoma: a single-institution experience using aggressive multimodal therapy. Thyroid. 2011, 21: 25-30. 10.1089/thy.2010.0220.CrossRefPubMed
15.
go back to reference Sugitani I, Miyauchi A, Sugino K, Okamoto T, Yoshida A, Suzuki S: Prognostic factors and treatment outcomes for anaplastic thyroid carcinoma: ATC Research Consortium of Japan cohort study of 677 patients. World J Surg. 2012, 36: 1247-1254. 10.1007/s00268-012-1437-z.CrossRefPubMed Sugitani I, Miyauchi A, Sugino K, Okamoto T, Yoshida A, Suzuki S: Prognostic factors and treatment outcomes for anaplastic thyroid carcinoma: ATC Research Consortium of Japan cohort study of 677 patients. World J Surg. 2012, 36: 1247-1254. 10.1007/s00268-012-1437-z.CrossRefPubMed
16.
go back to reference Tanaka K, Sugitani I, Fujimoto Y: A novel chemo-radiotherapy with low-dose daily cisplatin, 5-fluorouracil and doxorubicin for anaplastic thyroid carcinoma: a preliminary report. Jpn J Clin Oncol. 2011, 41: 1074-1078. 10.1093/jjco/hyr095.CrossRefPubMed Tanaka K, Sugitani I, Fujimoto Y: A novel chemo-radiotherapy with low-dose daily cisplatin, 5-fluorouracil and doxorubicin for anaplastic thyroid carcinoma: a preliminary report. Jpn J Clin Oncol. 2011, 41: 1074-1078. 10.1093/jjco/hyr095.CrossRefPubMed
17.
go back to reference Perri F, Lorenzo GD, Scarpati GD, Buonerba C: Anaplastic thyroid carcinoma: a comprehensive review of current and future therapeutic options. World J Clin Oncol. 2011, 10: 150-157.CrossRef Perri F, Lorenzo GD, Scarpati GD, Buonerba C: Anaplastic thyroid carcinoma: a comprehensive review of current and future therapeutic options. World J Clin Oncol. 2011, 10: 150-157.CrossRef
18.
go back to reference Siironen P, Hagström J, Mäenpää HO, Louhimo J, Heikkilä A, Heiskanen I, Arola J, Haglund C: Anaplastic and poorly differentiated thyroid carcinoma: therapeutic strategies and treatment outcome of 52 consecutive patients. Oncology. 2010, 79: 400-408. 10.1159/000322640.CrossRefPubMed Siironen P, Hagström J, Mäenpää HO, Louhimo J, Heikkilä A, Heiskanen I, Arola J, Haglund C: Anaplastic and poorly differentiated thyroid carcinoma: therapeutic strategies and treatment outcome of 52 consecutive patients. Oncology. 2010, 79: 400-408. 10.1159/000322640.CrossRefPubMed
19.
go back to reference Higashiyama T, Ito Y, Hirokawa M, Fukushima M, Uruno T, Miya A, Matsuzuka F, Miyauchi A: Induction chemotherapy with weekly paclitaxel administration for anaplastic thyroid carcinoma. Thyroid. 2010, 20: 7-14. 10.1089/thy.2009.0115.CrossRefPubMed Higashiyama T, Ito Y, Hirokawa M, Fukushima M, Uruno T, Miya A, Matsuzuka F, Miyauchi A: Induction chemotherapy with weekly paclitaxel administration for anaplastic thyroid carcinoma. Thyroid. 2010, 20: 7-14. 10.1089/thy.2009.0115.CrossRefPubMed
20.
go back to reference Voigt W, Kegel T, Weiss M, Mueller T, Simon H, Schmoll HJ: Potential activity of paclitaxel, vinorelbine and gemcitabine in anaplastic thyroid carcinoma. J Cancer Res Clin Oncol. 2005, 131: 585-590. 10.1007/s00432-005-0673-0.CrossRefPubMed Voigt W, Kegel T, Weiss M, Mueller T, Simon H, Schmoll HJ: Potential activity of paclitaxel, vinorelbine and gemcitabine in anaplastic thyroid carcinoma. J Cancer Res Clin Oncol. 2005, 131: 585-590. 10.1007/s00432-005-0673-0.CrossRefPubMed
21.
go back to reference Pudney D, Lau H, Ruether JD, Falck V: Clinical experience of the multimodality management of anaplastic thyroid cancer and literature review. Thyroid. 2007, 17: 1243-1250. 10.1089/thy.2007.0026.CrossRefPubMed Pudney D, Lau H, Ruether JD, Falck V: Clinical experience of the multimodality management of anaplastic thyroid cancer and literature review. Thyroid. 2007, 17: 1243-1250. 10.1089/thy.2007.0026.CrossRefPubMed
22.
go back to reference Troch M, Koperek O, Scheuba C, Dieckmann K, Hoffmann M, Niederle B, Raderer M: High efficacy of concomitant treatment of undifferentiated (anaplastic) thyroid cancer with radiation and docetaxel. J Clin Endocrinol Metab. 2010, 95: E54-E57. 10.1210/jc.2009-2827.CrossRefPubMed Troch M, Koperek O, Scheuba C, Dieckmann K, Hoffmann M, Niederle B, Raderer M: High efficacy of concomitant treatment of undifferentiated (anaplastic) thyroid cancer with radiation and docetaxel. J Clin Endocrinol Metab. 2010, 95: E54-E57. 10.1210/jc.2009-2827.CrossRefPubMed
Metadata
Title
Outcome after intensity modulated radiotherapy for anaplastic thyroid carcinoma
Authors
Xiayun He
Duanshu Li
Chaosu Hu
Zhuoying Wang
Hongmei Ying
Yi Wu
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2014
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-14-235

Other articles of this Issue 1/2014

BMC Cancer 1/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine